Uscom Limited today announced the raising of $1.065m in a combined private placement to new and current sophisticated investors and exercise of options by staff. The funds will be directed to support current sales and marketing initiatives and new distribution partnerships. The issue was managed by brokers Lodge Partners.
Executive Chairman of Uscom, Rob Phillips said, "Uscom has two premium cardiovascular products and we are focused on getting a dominant position for these products in the global market. This will involve high quality sales and distribution partnerships of depth and breadth. These funds will support the transition to this sales and marketing strategy and provide for inventory replenishment and manufacturing to fill orders."
Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, both with regulatory approval. The USCOM is a practice leading ultrasonic cardiac output monitor with proven application in sepsis, hypertension and heart failure. The BP+ is the premium supra systolic Central Blood Pressure monitor for the identification and management of hypertension and heart failure. Central BP is the new standard of care for monitoring blood pressure replacing simple arm measurement technologies by measuring the BP at the level of the heart; the Uscom BP+ is the emerging central BP monitoring technology.
distributed by
 |